Science News
from research organizations

Post-biotics may help shield obese from diabetes

Date:
April 20, 2017
Source:
McMaster University
Summary:
It was previously thought that bacteria only caused problems such as higher inflammation and higher blood glucose. But this is only half of the story. Now researchers have discovered that a specific component of bacteria actually lowers blood glucose and allows insulin to work better during obesity.
Share:
FULL STORY

You've heard of pre-biotics and pro-biotics, but now you'll be hearing a lot more about post-biotics. Researchers at McMaster University have begun to identify how post-biotics, or the by-products of bacteria, lower blood glucose and allow insulin to work better.

Jonathan Schertzer, assistant professor of biochemistry and biomedical sciences and senior author of a paper published by Cell Metabolism, explains it this way: "We know that gut bacteria, often called the microbiome, send inflammation signals that change how well insulin works to lower blood glucose.

"It was previously thought that bacteria only caused problems such as higher inflammation and higher blood glucose. But this is only half of the story. We discovered that a specific component of bacteria actually lowers blood glucose and allows insulin to work better during obesity.

"Understanding how different parts of bacteria control glucose could lead to new therapies that avoid some of the problems with pro-biotics or pre-biotics. We have found a "post-biotic" that lowers blood glucose during obesity."

This work is important as more than half of Canadians are overweight or obese, which leads to higher levels of blood insulin and glucose. These features of prediabetes can lead to type 2 diabetes.

"But we haven't understood what triggers elevated blood glucose," said Schertzer. "This is significant because only some individuals with obesity develop prediabetes. Blood glucose is influenced by our genes, the food we eat, and the bacteria in our gut."

His research team is working to develop new bacterial-based drugs to lower blood glucose and combat prediabetes before type 2 diabetes develops. At this time, they have had success in trials with mice with a drug currently used for osteosarcoma, a bone cancer.


Story Source:

Materials provided by McMaster University. Note: Content may be edited for style and length.


Journal Reference:

  1. Joseph F. Cavallari, Morgan D. Fullerton, Brittany M. Duggan, Kevin P. Foley, Emmanuel Denou, Brennan K. Smith, Eric M. Desjardins, Brandyn D. Henriksbo, Kalvin J. Kim, Brian R. Tuinema, Jennifer C. Stearns, David Prescott, Philip Rosenstiel, Brian K. Coombes, Gregory R. Steinberg, Jonathan D. Schertzer. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metabolism, 2017; DOI: 10.1016/j.cmet.2017.03.021

Cite This Page:

McMaster University. "Post-biotics may help shield obese from diabetes." ScienceDaily. ScienceDaily, 20 April 2017. <www.sciencedaily.com/releases/2017/04/170420132508.htm>.
McMaster University. (2017, April 20). Post-biotics may help shield obese from diabetes. ScienceDaily. Retrieved May 27, 2017 from www.sciencedaily.com/releases/2017/04/170420132508.htm
McMaster University. "Post-biotics may help shield obese from diabetes." ScienceDaily. www.sciencedaily.com/releases/2017/04/170420132508.htm (accessed May 27, 2017).

RELATED STORIES